News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Johnson & Johnson (JNJ) Earnings Exceed Expectations



10/17/2012 7:13:21 AM

Healthcare giant Johnson & Johnson reported better-than-expected third-quarter results on Tuesday, as newer drugs, including a treatment for prostate cancer, led a rebound in sales and investor jitters about medical device sales proved unfounded. J&J, whose products span artificial hips and over-the-counter painkillers like Tylenol, is showing signs of dependable sales growth after several years of navigating costly product recalls and the loss of patent protection on major brand-name drugs. Its performance has been helped by the launch of prescription drugs like Zytiga for prostate cancer and Incivek for hepatitis C, which it sells abroad under license from Vertex Pharmaceuticals Inc, as well as the nearly $20 billion purchase of Swiss medical device maker Synthes earlier this year. "Things can't help but look more positive for the company with today's results," said Piper Jaffray analyst Matt Miksic, who noted it was the first time in a year that J&J had beaten Wall Street sales estimates. Earnings per share before special items topped expectations, and revenue also beat Wall Street estimates. For a graphic, see: link.reuters.com/wef43t

Read at Reuters
Read at Fox News
Read at RTT News
Read at 24/7 Wall St.
Read at Financial Post


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES